SCHEMBL2162128

SCHEMBL2162128

CC1OCc2sc(NC(=O)C3C(C)(C)C3(C)C)c(C(=O)C3CCC3)c21

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.44
CNR1 P21554 3/20 0.44
RAB7A P51149 1/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 3/20 0.35
HSD17B10 Q99714 2/20 0.35
MAPT P10636 2/20 0.35
ALDH1A1 P00352 4/20 0.34
MEN1 O00255 1/20 0.34
FLT3 P36888 1/20 0.34
TSHR P16473 2/20 0.33
HPGD P15428 2/20 0.33
MAPK10 P53779 1/20 0.33
MDM2 Q00987 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163111 0.84 CNR2 (0.46) CNR2CNR1RAB7AKMT2AKDM4E
SCHEMBL2162073 0.79 KMT2A (0.51) CNR2CNR1KMT2AKDM4EHSD17B10
SCHEMBL2163620 0.79 RAB7A (0.42) CNR2CNR1RAB7AKMT2AKDM4E
SCHEMBL2162410 0.78 CNR1 (0.46) CNR2CNR1KDM4EALDH1A1L3MBTL1
SCHEMBL2163738 0.78 CNR2 (0.47) CNR2CNR1
SCHEMBL2163174 0.77 CNR1 (0.37) CNR2CNR1RAB7AKMT2AKDM4E
SCHEMBL2162596 0.77 CNR2 (0.70) CNR2CNR1
SCHEMBL2162362 0.76 CNR2 (0.47) CNR2CNR1
SCHEMBL2162393 0.75 CNR1 (0.38) CNR2CNR1KMT2AKDM4EHSD17B10
SCHEMBL5453373 0.75 FLT3 (0.54) CNR2CNR1KMT2AKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US claimed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US claimed
WO-2008028094-A1 COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 WO claimed
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US disclosed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, OPRL1 CNR2 2/4885CNR1 1/4885RAB7A 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.